

1 **Viral kinetics of sequential SARS-CoV-2 infections**

2
3 Stephen M Kissler¹, James A Hay², Joseph R Fauver³, Christina Mack⁴, Caroline G Tai⁴, Deverick J An-
4 derson⁵, David D Ho⁶, Nathan D Grubaugh⁷, Yonatan H Grad¹

5
6 ¹ Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston
7 MA USA

8 ² Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford,
9 UK

10 ³ Department of Epidemiology, University of Nebraska Medical Center, Omaha NE USA

11 ⁴ IQVIA, Durham NC USA

12 ⁵ Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham NC USA

13 ⁶ Vagelos College of Physicians and Surgeons, Columbia University, New York NY USA

14 ⁷ Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven CT USA

15
16
17 **Abstract.** The impact of a prior SARS-CoV-2 infection on the progression of subsequent infec-
18 tions has been unclear. Using a convenience sample of 94,812 longitudinal RT-qPCR measure-
19 ments from anterior nares and oropharyngeal swabs, we compared the SARS-CoV-2 viral kinetics
20 of first vs. second infections, adjusting for viral variant, vaccination status, and age. Relative to
21 first infections, second infections usually featured a lower peak viral concentration and faster
22 clearance time, especially in individuals who received a vaccine dose between their first and sec-
23 ond infection. Furthermore, a person's relative (rank-order) viral clearance time, compared to oth-
24 ers infected with the same variant, was similar across first and second infections; that is, individ-
25 uals who had a relatively fast clearance time in their first infection tended to also have a relatively
26 fast clearance time in their second infection. These findings provide evidence that, like vaccina-
27 tion, immunity from a prior SARS-CoV-2 infection shortens the duration of subsequent acute
28 SARS-CoV-2 infections principally by reducing viral clearance time. Additionally, there appears
29 to be an inherent element of the immune response, or some other host factor, that shapes a
30 person's relative ability to clear SARS-CoV-2 infection that persists across sequential infections.

31
32 **Key words.** Viral kinetics; SARS-CoV-2; reinfection; clearance

33 **Introduction.**

34
35 An estimated 65% of the US population had at least two SARS-CoV-2 infections by November
36 2022, but the impact of prior infection on disease course in subsequent infections has been de-
37 bated.¹ Some evidence indicates SARS-CoV-2 infection provides a temporary reduction in re-
38 infection risk² and a durable reduction in the risk of COVID-19-related hospitalization and death,³
39 while a handful of studies suggest that an initial SARS-CoV-2 infection may limit recovery from
40 COVID-19 infections.⁴ These contrasting findings may result from biases that can arise in popu-
41 lation-level studies when differences in exposure history, vaccination status, and comorbidities
42 are not fully accounted for. Controlling for such factors is a major challenge given geographically
43 and temporally heterogeneous interventions, whereas examining the dynamics of SARS-CoV-2
44 infections at the individual level can facilitate adjusting for these biases.

45
46 Reverse transcription quantitative PCR (RT-qPCR) conducted from clinical samples collected at
47 multiple time points offer an objective, quantitative metric of SARS-CoV-2 kinetics and can inform
48 on key aspects of immune response and clinical progress. Such data have been used to specify
49 how vaccination history, antibody titer and viral lineage together shape SARS-CoV-2 proliferation
50 and clearance during an acute infection,⁵ which in turn can inform the clinical management of
51 COVID-19⁶ and help interpret epidemiological trends.⁷ Viral kinetics therefore offer a promising
52 metric for clarifying the impact of an initial SARS-CoV-2 infection on subsequent infections and
53 for translating those findings into medical and public health guidance.

54
55 The impact of vaccination and variant on SARS-CoV-2 viral kinetics have been well described
56 elsewhere.^{8–13} Infections with Delta lineages feature a higher peak viral concentration than Alpha
57 or Omicron infections, and vaccination speeds up the clearance of SARS-CoV-2 across line-
58 ages.¹¹ However, the impact of SARS-CoV-2 infection-conferred immunity on peak viral concen-
59 tration, viral proliferation, and viral clearance in subsequent infections is less well characterized.
60 Furthermore, it has been unclear to what extent attributes of SARS-CoV-2 kinetics, such as peak
61 viral load or clearance rate, persist across an individual's successive infections.

62
63 Here, we collected and analyzed 94,812 SARS-CoV-2 RT-qPCR viral concentration measure-
64 ments taken from longitudinal clinical samples in players, staff, and affiliates of the National Bas-
65 ketball Association (NBA) between March 11th, 2020, and July 28th, 2022. For the subset of indi-
66 viduals who were infected twice during the study period, we measured changes in viral kinetics
67 between first and second infections and determined the extent to which viral kinetic features per-
68 sisted across infections.

69
70 **Methods.**

71
72 Study design. Between March 11th, 2020, and July 28th, 2022, the NBA conducted regular surveil-
73 lance for SARS-CoV-2 infection among players, staff, and affiliates as part of an occupational
74 health program. This included frequent viral testing (often daily during high community COVID-19

75 prevalence) using a variety of platforms, but primarily via nucleic acid amplification tests, as well
76 as clinical assessment including case diagnosis and symptom tracking. To assess viral concen-
77 tration, RT-qPCR tests were conducted when possible, using anterior nares and oropharyngeal
78 swabs collected by a trained professional and combined into a single viral transport media. Cycle
79 threshold (Ct) values were obtained from the Roche cobas target 1 assay. Ct values were con-
80 verted to genome equivalents per milliliter using a standard curve.¹⁴ Data on participant age and
81 vaccination status were collected where possible. Viral lineages were assigned using whole-ge-
82 nome sequencing (**Supplementary Methods**), when feasible. This resulted in a longitudinal da-
83 taset of 424,401 SARS-CoV-2 tests with clinical COVID-19 history and demographic information
84 for 3,021 individuals.

85
86 During the data collection period, 3,346 infections were identified among the 3,021 individuals.
87 These infections reflected the timing, intensity, and lineage composition of SARS-CoV-2 trans-
88 mission in the broader United States (**Figure 1**). Of these infections, we identified 1,989 “well-
89 documented” infections that were sufficiently sampled to infer viral kinetics (**Table 1**), as defined
90 by at least one RT-qPCR test with cycle threshold (Ct) value under 32 and three tests with Ct
91 values under 40¹¹ One individual had four total infections, and we omitted their third and fourth
92 from the analysis. Of the well-documented infections, 193 were second infections, as evidenced
93 by a previous positive test more than 30 days prior to infection or a clinical history of prior infection
94 (**Figure 1, Supplementary Table 1**).

95
96 Vaccination status (unvaccinated, fully vaccinated, or boosted) was assigned at the time of the
97 first positive test for each infection. Full vaccination corresponded to 14 days following either the
98 second dose of a Pfizer or Moderna vaccine or the first dose of a Johnson and Johnson/Janssen
99 vaccine. A person was considered “boosted” 14 days after an additional Pfizer or Moderna dose
100 following their initial vaccination course.

101
102 Estimating viral kinetic parameters. We characterized the viral kinetics of the well-documented
103 infections by fitting a hierarchical piecewise linear model to the viral concentration measurements
104 on a logarithmic scale, following previous methods.^{11,14} The model captures the viral proliferation
105 time (*i.e.*, time from first possible detection to peak), peak viral concentration, and clearance time
106 (*i.e.*, time from peak to last possible detection) of acute SARS-CoV-2 infections. The hierarchical
107 structure allowed us to estimate population-level differences in viral kinetic parameters associated
108 with vaccination status, viral lineage, and history of a prior SARS-CoV-2 infection. We adjusted
109 the model fits by the age group of the infected individual (0–29 years, 30–49 years, and 50+
110 years). Model parameters were fit using a Hamilton Monte Carlo algorithm implemented in R
111 (version 4.1.2) and Stan (version 2.21.3).

112
113 Study outcomes. We assessed whether Omicron BA.1/BA.2 viral kinetics differed according to
114 whether the infection was the individual’s first SARS-CoV-2 infection ($n = 1,241$ well-documented
115 infections) or their second infection ($n = 159$ well-documented infections; **Supplementary Table**
116 **1, group 1**), stratifying by booster status and adjusting for age. Then, for the subset of individuals

117 with a first infection by a non-Omicron lineage (verified by whole-genome sequencing or an infec-
118 tion onset prior to November 11th, 2021) and a second infection with BA.1 or BA.2 ($n = 235$ well-
119 documented infections among 177 individuals; **Supplementary Table 1, group 2**), we estimated
120 (a) the difference in mean viral kinetics (proliferation time, clearance time, and peak viral load)
121 between first and second infections and (b) the difference in viral kinetics of a second BA.1/BA.2
122 infection associated with the variant category of the first infection (Alpha, Delta, or other lineages).
123 We note that individuals who underwent two infections may differ from the rest of the population
124 in terms of their exposure patterns, immunity, and/or sampling patterns. Last, using the subset of
125 individuals ($n = 58$; **Supplementary Table 1, group 3**) with two well-documented infections, we
126 assessed whether a person's relative individual-level viral kinetic features (proliferation time,
127 clearance time, or peak viral load) persisted across infections.

128
129 Statistical approach. We assessed differences in viral kinetic parameters across category subsets
130 (e.g., by presence/absence of a prior infection or by vaccination status) by subtracting the relevant
131 posterior draws and measuring the posterior probability mass of these differences that sat
132 above/below 0, depending on the scenario. When fewer than 5% of these differenced posterior
133 draws sat above/below zero, we took this as evidence of a significant difference.

134
135 To assess relative persistence in individual-level viral kinetic attributes across infections, we
136 measured the Spearman correlation between the rank of the viral kinetic parameter in the first
137 infection and the rank of the same parameter for the same person in the second infection, relative
138 to all other infections caused by the same variant in individuals with two well-documented infec-
139 tions (**Supplementary Methods**). We used Spearman correlation because, as a rank-based
140 measure, it is less affected by outliers and non-linear relationships between the viral kinetics in
141 the first and second infection. As a sensitivity analysis, we repeated the analysis using the more
142 common Pearson correlation (**Supplementary Methods**). To assess the statistical significance
143 of the correlations, we conducted permutation tests, randomly assigning first- and second-infec-
144 tion viral kinetic parameters to different individuals and re-calculating the correlation. We then
145 compared the true correlation to the distribution of correlations achieved through 100,000 permu-
146 tations and concluded a significant difference when the true correlation was higher than 95% of
147 the correlations obtained from permutation.

148
149 Study oversight. This work was approved as “research not involving human subjects” by the Yale
150 Institutional Review Board (HIC protocol # 2000028599), as it involved de-identified samples. This
151 work was also designated as “exempt” by the Harvard Institutional Review Board (IRB20-1407).

152
153 **Results.**

154
155 In BA.1/BA.2 infections, evidence of a previous infection correlates with faster clearance. Omicron
156 BA.1/BA.2 infections in individuals with a history of prior infection ($n = 159$) featured a faster mean
157 clearance time (4.9 days (4.5, 5.3)) than Omicron BA.1/BA.2 infections in individuals with no prior
158 infection history ($n = 1,241$; 7.2 days (6.8, 7.5)) (**Figure 2A–B; Supplementary Table 1, group**

159 **1).** Even in individuals who had received a booster vaccine dose, BA.1/BA.2 clearance times were
160 faster in individuals with a history of prior infection (5.1 days (4.5, 5.7)) than in those with no such
161 history (7.1 days (6.7, 7.6); **Supplementary Table 2**). Omicron BA.1/BA.2 clearance rates were
162 also faster in vaccine-boosted individuals with a history of prior infection (2.6 Ct/day (2.2, 3.0))
163 than in those without (2.0 Ct/day (1.8, 2.1); **Supplementary Table 2**). The reduction in second-
164 infection clearance time also resulted in greater symmetry between proliferation and clearance
165 times (ratio of proliferation time to clearance time: 0.7 (0.6, 0.8) for the $n = 1,241$ BA.1/BA.2 in-
166 fections with no prior infection history vs. 0.9 (0.7, 1.0) for the $n = 159$ BA.1/BA.2 infections with
167 prior infection history).

168
169 In individuals with multiple infections, second infections were cleared faster than first infections,
170 especially when there was an intervening vaccine dose. We found no significant difference in
171 proliferation time or peak viral concentration between first infections caused by Alpha, Delta, or
172 other/unspecified lineages in individuals with a later Omicron BA.1/BA.2 infection ($n = 78$) vs.
173 second infections caused by Omicron BA.1 or BA.2 in individuals with a previous Alpha, Delta, or
174 other/unspecified infection ($n = 157$) (**Supplementary Table 1, group 2**). However, in this group,
175 clearance times were substantially faster in second infections (5.1 days (4.7, 5.7) vs. 8.8 days
176 (7.8, 9.8) in first infections, **Supplementary Table 3**). Clearance rates were also substantially
177 faster in second infections within this group (2.4 Ct/day (2.1, 2.7) vs. 1.6 Ct/day (1.3, 1.8) in first
178 infections, **Supplementary Table 3**). Individuals in this group who had an intervening vaccine
179 dose between their first and second infection had a somewhat faster mean second-infection viral
180 clearance time than those without an intervening dose (5.2 days (4.5, 9.5) with an intervening
181 dose; 6.2 days (4.2, 8.8) without an intervening dose), though these estimates carry substantial
182 uncertainty (**Figure 2C–F, Supplementary Table 3**). As before, the reduction in second-infection
183 clearance time also resulted in greater symmetry between proliferation and clearance times (ratio
184 of proliferation time to clearance time: 0.4 (0.3, 0.6) for the $n = 78$ first infections vs. 0.9 (0.7, 1.1)
185 for the $n = 157$ second infections).

186
187
188 No evidence that the kinetics of a second infection by BA.1/BA.2 differ according to the first infec-
189 tion's lineage. We found no evidence the variant category of a previous infection (Alpha vs. Delta
190 vs. other/unspecified) affected the mean viral kinetics of a later Omicron BA.1/BA.2 infection ($n =$
191 157 , **Supplementary Table 1 group 2; Supplementary Table 5**). That is, regardless of the line-
192 age of the initial infection, the viral kinetics of second BA.1/BA.2 infections had similar features to
193 one another, though not to the first infection.

194
195 An individual's relative clearance speed is preserved across infections. Among individuals with
196 two well-documented infections ($n = 58$; **Supplementary Table 1, group 3**), the ranking of clear-
197 ance times was roughly conserved across first and second infections; that is, those with a rela-
198 tively short clearance time in their first infection tended to have a short clearance time in their
199 second infection, and *vice versa* (**Figure 3**). The Spearman correlation coefficient between indi-
200 vidual-level mean clearance times for first vs. second infections was 0.475 overall ($p = 0.0001$,

201 permutation test). When stratified by the variant category of the first infection, the Spearman cor-
202 relation between individual-level mean clearance times for first vs. second infections was 0.783,
203 0.352, and 0.396 for Alpha, Delta, and infections with other/unspecified lineages, respectively.
204 We found somewhat weaker evidence that a person's proliferation time rank was conserved
205 across infections, with a Spearman correlation coefficient of 0.267 ($p = 0.02$, permutation test) for
206 first vs. second infections. We did not find evidence that an individual's peak viral concentration
207 rank was maintained across infections. These findings were robust to the choice of correlation
208 statistic (Pearson vs. Spearman; **Supplementary Table 6**).

209

210 **Discussion.**

211

212 In individuals with multiple infections, second infections were cleared more quickly than first in-
213 fections, especially when there was an intervening vaccine dose between the two infections. The
214 lineage of the first infection did not meaningfully affect the viral kinetics of a later BA.1/BA.2 infec-
215 tion. However, one's relative speed of clearing infection persisted across infections: those with a
216 relatively fast clearance speed in their first infection tended to have a relatively fast clearance
217 speed in their second infection, and *vice versa*, when compared to others infected with the same
218 variant. Thus, while prior infection and vaccination can modulate a person's viral kinetics in abso-
219 lute terms, there may also exist some further immunological mechanism, conserved across se-
220 quential infections, that determines one's strength of immune response against SARS-CoV-2 re-
221 lative to others in the population.

222

223 The mechanism underlying this persistence in clearance speed rank across subsequent infections
224 is unclear. Some possibilities include the recency of exposure to a different related coronavirus
225 (e.g., HKU1 or OC43),¹⁵ immune imprinting from early-lifetime exposure to certain coronavirus
226 lineages,¹⁶ or an inherent, genome-mediated aspect of immune response. It is also unclear
227 whether one's relative ability to clear SARS-CoV-2 infection generalizes to other coronaviruses
228 or to other pathogens. Serological studies and genome-wide association studies may help to illu-
229 minate the mechanisms behind persistence in SARS-CoV-2 clearance time. Such studies would
230 be valuable for improving our basic understanding of immune response to respiratory pathogens
231 and for developing personalized clinical respiratory disease management protocols.

232

233 A consistent finding between this and other studies on SARS-CoV-2 viral kinetics is that prior
234 antigenic exposure, through infection or vaccination, tends to speed up viral clearance, and thus
235 to reduce the duration of test positivity.^{5,11,17} The duration of viral positivity has various conse-
236 quences both for clinical management and for public health surveillance. For clinical manage-
237 ment, test results should be interpreted in the context of a patient's immune history, which can
238 modulate both the extent and expected duration of viral shedding.^{5,14} It may also be possible to
239 adjust the recommended duration of post-infection isolation based on infection history. When es-
240 timating epidemic growth rates using cross-sectional RT-qPCR test results, it is critical to account
241 for immune-mediated shifts in the asymmetry between viral clearance to viral proliferation times,

242 since this asymmetry is a key component in determining whether an epidemic is growing or shrink-
243 ing.⁷ We find that the difference between viral proliferation and viral clearance times decreases in
244 second infections, which may reduce certainty in epidemic growth rates derived from cross-sec-
245 tional RT-qPCR-based methods.

246
247 This study is limited by various factors. The cohort is predominately young, male, and healthy.
248 While we adjusted for age, comorbidities and other underlying health factors were not measured.
249 We were unable to fully disentangle the effect of both variant and first vs. second infection simul-
250 taneously due to small sample sizes when the population was separated into such narrow cate-
251 gories. Still, our findings are consistent with other studies showing that immunity tends to reduce
252 clearance time;^{5,11,17} thus, we expect that our findings of relatively lower peak viral load and faster
253 clearance in second infections are at least partially features of immune response and not just to
254 viral lineage alone. This study focuses primarily on individuals who were ultimately infected twice,
255 and these individuals may differ in important immunological and behavioral ways from those who
256 only underwent one infection during the study period. This underscores the need for further stud-
257 ies that capture viral and serological kinetics in tandem.


258
259 In conclusion, immunity from a first SARS-CoV-2 infection affects the viral kinetics of a second
260 SARS-CoV-2 infection principally by speeding up viral clearance and thus shortening the overall
261 time of acute infection. The kinetics of a second BA.1/BA.2 infection are unaffected by the lineage
262 of the first infection. Individuals who quickly cleared their first infection also tended to quickly clear
263 their second infection, pointing towards persistence of underlying immune response across mul-
264 tiple infections. These findings help guide the interpretation of quantitative SARS-CoV-2 tests
265 both clinically and for surveillance and point towards persistent individual-level immune mecha-
266 nisms against SARS-CoV-2 that so far remain unexplained.

267 **Table 1. Characteristics of the well-documented infections.** Counts by lineage, vaccination status, age
 268 group, and cardinality of infection (first, second, third, or fourth) for the 1,989 well-documented infections.
 269 Well-documented infections are those with at least one RT-qPCR Ct < 32 and three Ct < 40 (the limit of
 270 detection). Infections occurred between 11th March 2020 and 28th July 2022.


Statistic	Category	N	%
Total		1989	100
Lineage + vaccination status at time of infection	Alpha	49	2.5
	Unvaccinated	24	1.2
	Vaccinated	4	0.2
	Unknown primary vaccination status	21	1.1
	Unboosted	22	1.1
	Boosted	0	0.0
	Unknown booster status	27	1.4
	Delta	191	9.6
	Unvaccinated	7	0.4
	Vaccinated	123	6.2
	Unknown primary vaccination status	61	3.1
	Unboosted	99	5.0
	Boosted	10	0.5
	Unknown booster status	82	4.1
	BA.1/BA.2	1400	70.4
	Unvaccinated	6	0.3
	Vaccinated	994	50.0
	Unknown primary vaccination status	400	20.1
	Unboosted	117	5.9
	Boosted	778	39.1
	Unknown booster status	507	25.5
BA.4/BA.5	71	3.6	
Unvaccinated	0	0.0	
Vaccinated	53	2.7	
Unknown primary vaccination status	18	0.9	
Unboosted	0	0.0	
Boosted	50	2.5	
Unknown booster status	21	1.1	
Other/Unspecified	278	14.0	
Unvaccinated	98	4.9	
Vaccinated	81	4.1	
Unknown primary vaccination status	99	5.0	
Unboosted	92	4.6	
Boosted	55	2.8	
Unknown booster status	131	6.6	
Age group	0-29	816	41.0
	30-49	876	44.0
	50-99	295	14.8
	Not Reported	2	0.1
Infection number	1	1796	90.3
	2	193	9.7

271
272

273
274



275
276



277
278




279
280


281 **Figure 1. Onset times of repeat and overall infections in the dataset.** (A): Histogram of first positive
282 test dates for all recorded infections in full dataset ($n = 3,346$). Colors in both panels correspond to the
283 SARS-CoV-2 variant category (Other/Unspecified: Black; Alpha: Blue; Delta: Red; BA.1/BA.2: Magenta),
284 where Other/Unspecified include all non-Alpha, Delta, and Omicron lineages and any samples that could
285 not be sequenced. (B): Date of the first positive test (points) for well-documented infections ($n = 235$) in
286 individuals with an initial Alpha, Delta, or Other/Unspecified infection ($n = 78$ well-documented infections)
287 and a second BA.1/BA.2 infection ($n = 157$ well-documented infections; see also **Supplementary Table 1,**
288 **group 2**). Horizontal lines connect the points that correspond to multiple infections that belong to a single
289 person. Lines that extend off the plot range to the left indicate the absence of a well-documented (though
290 clinically confirmed) first infection, and lines that extend off the plot range to the right indicate the absence
291 of a well-documented (though clinically confirmed) second infection.

292

293



294



295

296

297

298

299

300

301

302

303

304

305

306

307

308


309

310

Figure 2. Viral kinetics of first vs. second infections. (A–B): Mean posterior viral trajectory (solid lines) with 95% credible interval (shaded region) for well-documented BA.1/BA.2 infections in individuals where the infection was (A) their first recorded SARS-CoV-2 infection ($n = 1,241$) or (B) their second recorded SARS-CoV-2 infection ($n = 159$; see **Supplementary Table 1, group 1**). (C–F): Mean posterior viral trajectory (solid lines) with 95% credible interval (shaded region) for well-documented infections in individuals who were infected twice during the study period. Panels (C, E) depict the viral kinetics of first Alpha/Delta/Other/Unspecified infections in unvaccinated (C, $n = 42$) and vaccinated (E, $n = 15$) individuals who later had a BA.1/BA.2 infection. Panels (D, F) depict the viral kinetics of second BA.1/BA.2 infections in individuals who did not have a vaccine dose between their first and second infection (D, $n = 5$) and in individuals who did have a vaccine dose between their first and second infection (F, $n = 102$) as well as a previous Alpha/Delta/Other/Unspecified infection (**Supplementary Table 1, group 2**, omitting any individuals with unknown vaccination status). In all panels, grey points depict the measured viral concentration for a single test. For each person, the points were shifted horizontally so that the individual's mean posterior peak viral concentration sits at day 0. Black points and whiskers (A, C, E) depict the mean and 95% credible interval for the proliferation time, peak viral concentration, and clearance time, from left to right, for first


311 infections. These values are repeated in grey on the lower plots (B, D, F) to facilitate comparison with the
312 viral kinetics of second infections.
313

314 A)




315
316

317 B)




C)



318
319

D)



320

321
322 **Figure 3. Relative viral kinetic parameters for first vs. second SARS-CoV-2 infections.** (A): Spearman
323 correlation (points) of peak viral load, proliferation time, and clearance time for first vs. second infections
324 among $n = 58$ individuals with two well-documented infections (**Supplementary Table 1, group 3**). The
325 height of the grey shaded area is proportional to the probability that the Spearman correlation would fall at
326 a particular value given no correlation between first- and second-infection parameters. (B-D): Scatter plots
327 of the normalized order statistics (points) for the peak viral concentration (B), proliferation time (C), and
328 clearance time (D) for first vs. second infections in the $n = 58$ individuals with two well-documented infec-
329 tions. Points are colored according to the variant of the first infection (Other/None: black; Alpha: blue; Delta:
330 red); all second infections were caused by BA.1/BA.2. Dashed lines depict the best-fit linear regression to
331 the normalized order statistics when stratified by the variant of the first infection. The solid black line depicts
332 the overall best-fit linear regression to the normalized order statistics combined across all first-infection
333 variants. The grey regions depict the 95% confidence regions for this overall trend line. Order statistics
334 were calculated by ranking the mean posterior values for each parameter (peak viral load, proliferation time,
335 clearance time) for each infection within a variant/cardinality group (*e.g.*, Delta/first infection). Then, these
336 ranks were divided by the maximum rank for that variant/cardinality group, so that the normalized order
337 statistics fall between 0 and 1.

Supplementary Methods.

Genome sequencing and lineage alignment. Following previously described methods, RNA was extracted from clinical samples and confirmed as SARS-CoV-2 positive.¹⁸ Sequencing was performed using the Illumina COVIDSeq ARTIC viral amplification primer set (V4, 384 samples, cat# 20065135). Library preparation was performed using the amplicon-based Illumina COVIDseq Test v033 and sequenced 2x74 on Illumina NextSeq 550 following Illumina's documentation. The resulting FASTQ files were processed and analyzed on Illumina BaseSpace Labs using the Illumina DRAGEN COVID Lineage Application;¹⁹ versions included were 3.5.0, 3.5.1, 3.5.2, 3.5.3, and 3.5.4. The DRAGEN COVID Lineage pipeline was run with default parameters as recommended by Illumina. Lineage assignment and phylogenetics analysis were accomplished using the most recent versions of Pangolin²⁰ and NextClade,²¹ respectively.

Assessing persistence in viral kinetic parameters across infections. An individual's viral kinetics are expected to change substantially across subsequent infections due to the accumulation of immunity through both infection and vaccination and due to differences in viral lineage, among other factors. Furthermore, the impact that these factors have on viral kinetics may be non-linear and individual-specific. Because of this, a naïve measurement of similarity between viral kinetic parameter values in first vs. second infections is unlikely to yield valuable insights. However, more information might be obtained by comparing an individual's viral kinetics against those of similar individuals, in terms of variant and immune history, in first vs. second infections. This is the motivation for using the Spearman correlation for assessing associations in viral kinetic parameters across subsequent infections.

To measure the Spearman correlation between first and second infections for a given viral kinetic parameter, we first assigned a rank to the mean posterior value for that parameter for all individuals in an infection cardinality/variant group. That is, within each group of (a) first infections caused by Alpha, (b) first infections caused by Delta, (c) first infections caused by other/unspecified lineages, and (d) first infections caused by BA.1/BA.2, we ranked the viral kinetic parameter (say, peak viral load) from least to greatest. Next, we divided the ranks by the maximum rank for each group, so that the normalized ranks all fell between 0 and 1. Finally, we measured the correlation between the normalized ranks for all second vs. first all infections; this is the Spearman correlation. We normalized the values so that all the cardinality/variant groups would have a similar scale; the Spearman correlation is unaffected by such multiplicative normalizations. As a result, individuals with a normalized order statistic close to 1 had a large estimated value for the viral kinetic parameter relative to others in their cardinality/variant group, while individuals with a normalized order statistic close to 0 had a small estimated value for the viral kinetic parameter relative to others in their cardinality/variant group.

To assess robustness to this approach, we also measured the Spearman correlations fully stratified by the variant category of the first infection. That is, for each viral kinetic parameter, we measured the Spearman correlation three times, once for individuals whose first infection was caused by Alpha, once for individuals whose first infection was caused by Delta, and one for individuals whose first infection was caused by an other/unspecified lineage. Then, when normalizing the BA.1/BA.2 order statistics, we maintained these groups, so that the second infection for an individual who was previously infected by Alpha was only compared against other individuals who were also previously infected by Alpha. This stands in contrast to the previous approach, for which (a) all BA.1/BA.2 infections were ranked against one another regardless of the lineage of

386 the first infection and (b) once the order statistics were calculated for each infection cardinal-
387 ity/variant group, all first infections were combined to generate a single regression. These values
388 are reported in **Supplementary Table 7**.

389
390 We further assessed the sensitivity of this approach by calculating the standard Pearson correla-
391 tion between the viral kinetic parameters, using the raw estimated mean posterior values for each
392 person in their first and second infections (**Supplementary Figure 1, Supplementary Table 6**).
393 As expected, these relationships appear to be more subject to biases due to outlying trajectories,
394 but the general trends are the same: those with a relatively long clearance time in their first infec-
395 tion tended to have a long clearance time in their second infection, and *vice versa*, as measured
396 by a positive Pearson correlation between clearance times in first vs. second infections.

397 **Supplementary Table 1. Summary of well-documented infections by variant and lineage of any pre-**
 398 **ceding/following infection.** Counts of well-documented infections by infection cardinality (first vs. second),
 399 variant category (Alpha, Delta, BA./BA.2, BA.4/BA.5, Other/Unspecified), and the variant category of any
 400 preceding or following infection. The main results in this manuscript reflect a comparison between (1)
 401 BA.1/BA.2 first infections ($n = 1241$) vs. BA.1/BA.2 second infections ($n = 159$), (2) Alpha/Delta/Other/U-
 402 nspecified first infections that were followed by any BA.1/BA.2 infection ($n = 78$) vs. BA.1/BA.2 infections that
 403 were preceded by any Alpha/Delta/Other/Unspecified infection ($n = 157$), and (3) Alpha/Delta/Other/U-
 404 nspecified first infections that were followed by a well-documented BA.1/BA.2 infection ($n = 58$) vs. BA.1/BA.2
 405 infections that were preceded by a well-documented Alpha/Delta/Other/Unspecified infection ($n = 58$).
 406 Darker text indicates groups that are compared directly in the analyses described in the main results. Ar-
 407 rows connect the groups that are compared, with filled-in arrowheads denoting the “reference group” (first
 408 infections) and open arrowheads denoting the “comparison group” (second infections).

Infection number	<i>N</i>	Variant	<i>N</i>	Variant category of any preceding/following infection (well-documented or clinically confirmed)	<i>N</i>	Variant category of any preceding/following well-documented infection	<i>N</i>		
First	1796	Other/Unspecified	255	Followed by Alpha/Delta/Other/Unspecified	6	Followed by Alpha/Delta/Other/Unspecified	2		
			46	Followed by BA.1/BA.2	46	Followed by BA.1/BA.2	33		
		Alpha	48	Followed by Alpha/Delta/Other/Unspecified	3	Followed by Alpha/Delta/Other/Unspecified	0		
			14	Followed by BA.1/BA.2	14	Followed by BA.1/BA.2	12		
		Delta	191	Followed by Alpha/Delta/Other/Unspecified	9	Followed by Alpha/Delta/Other/Unspecified	3		
			18	Followed by BA.1/BA.2	18	Followed by BA.1/BA.2	13		
		BA.1/BA.2	1241	Followed by Alpha/Delta/Other/Unspecified	11	Followed by Alpha/Delta/Other/Unspecified	11	Followed by Alpha/Delta/Other/Unspecified	1
					13	Followed by BA.1/BA.2	13	Followed by BA.1/BA.2	2
				BA.4/BA.5	61	Followed by Alpha/Delta/Other/Unspecified	0	Followed by Alpha/Delta/Other/Unspecified	0
					0	Followed by BA.1/BA.2	0	Followed by BA.1/BA.2	0
		Second	193	Other/Unspecified	23	Preceded by Alpha/Delta/Other/Unspecified	22	Preceded by Alpha/Delta/Other/Unspecified	5
					1	Preceded by BA.1/BA.2	1	Preceded by BA.1/BA.2	1
				Alpha	1	Preceded by Alpha/Delta/Other/Unspecified	1	Preceded by Alpha/Delta/Other/Unspecified	0
					0	Preceded by BA.1/BA.2	0	Preceded by BA.1/BA.2	0
Delta	0			Preceded by Alpha/Delta/Other/Unspecified	0	Preceded by Alpha/Delta/Other/Unspecified	0		
	0			Preceded by BA.1/BA.2	0	Preceded by BA.1/BA.2	0		
BA.1/BA.2	159			Preceded by Alpha/Delta/Other/Unspecified	157	Preceded by Alpha/Delta/Other/Unspecified	157	Preceded by Alpha/Delta/Other/Unspecified	58
					2	Preceded by BA.1/BA.2	2	Preceded by BA.1/BA.2	2
				BA.5/BA.5	10	Preceded by Alpha/Delta/Other/Unspecified	5	Preceded by Alpha/Delta/Other/Unspecified	2
5	Preceded by BA.1/BA.2				5	Preceded by BA.1/BA.2	3		

409

410 **Supplementary Table 2. Viral kinetic parameters for BA.1/BA.2 infections, stratified by infection**
 411 **cardinality (first vs. second) and booster status and adjusted by age group.**

412

Viral kinetic parameter	Category	Value
Peak viral concentration (Ct)	First infection, unboosted	25.8 (24.8, 26.7)
	First infection, boosted	25.9 (25.3, 26.5)
	Second infection, unboosted	26.7 (25.0, 28.2)
	Second infection, boosted	27.0 (25.9, 28.0)
Peak viral concentration (GE/ml)	First infection, unboosted	6.6 (6.3, 6.9)
	First infection, boosted	6.6 (6.4, 6.7)
	Second infection, unboosted	6.4 (5.9, 6.8)
	Second infection, boosted	6.3 (6.0, 6.6)
Proliferation time (days)	First infection, unboosted	4.4 (3.8, 5.2)
	First infection, boosted	5.2 (4.7, 5.9)
	Second infection, unboosted	3.6 (2.7, 4.7)
	Second infection, boosted	4.6 (3.7, 5.7)
Clearance time (days)	First infection, unboosted	6.0 (5.5, 6.6)
	First infection, boosted	7.1 (6.7, 7.6)
	Second infection, unboosted	4.5 (3.8, 5.3)
	Second infection, boosted	5.1 (4.5, 5.7)
Proliferation rate (Ct/day)	First infection, unboosted	3.2 (2.7, 3.8)
	First infection, boosted	2.7 (2.4, 3.1)
	Second infection, unboosted	3.8 (2.7, 5.1)
	Second infection, boosted	2.9 (2.2, 3.6)
Clearance rate (Ct/day)	First infection, unboosted	2.4 (2.1, 2.6)
	First infection, boosted	2.0 (1.8, 2.1)
	Second infection, unboosted	3.0 (2.4, 3.6)
	Second infection, boosted	2.6 (2.2, 3.0)

413

414

415 **Supplementary Table 3. Viral kinetic parameters for first vs. second infections in individuals with**
 416 **multiple infections, stratified by vaccination status.**

417

Viral kinetic parameter	Category	Value
Peak viral concentration (Ct)	First infection, overall	26.3 (25.1, 27.5)
	First Infection, unvaccinated	26.7 (25.1, 28.2)
	First infection, vaccinated	27.0 (24.3, 29.4)
	Second infection, overall	27.6 (26.8, 28.5)
	Second Infection, no intervening dose	28.6 (24.6, 31.6)
	Second infection, intervening dose	27.9 (26.6, 29.1)
Peak viral concentration (GE/ml)	First infection, overall	6.4 (6.1, 6.8)
	First Infection, unvaccinated	6.3 (5.9, 6.8)
	First infection, vaccinated	6.3 (5.6, 7.0)
	Second infection, overall	6.1 (5.8, 6.3)
	Second Infection, no intervening dose	5.8 (5.0, 6.9)
	Second infection, intervening dose	6.0 (5.7, 6.4)
Proliferation time (days)	First infection, overall	3.8 (3.2, 4.6)
	First Infection, unvaccinated	4.1 (3.3, 5.1)
	First infection, vaccinated	3.7 (2.4, 5.3)
	Second infection, overall	4.4 (3.7, 5.2)
	Second Infection, no intervening dose	4.0 (2.4, 6.1)
	Second infection, intervening dose	4.5 (3.6, 5.6)
Clearance time (days)	First infection, overall	8.8 (7.8, 9.8)
	First Infection, unvaccinated	8.7 (7.7, 10.0)
	First infection, vaccinated	8.4 (6.5, 10.4)
	Second infection, overall	5.1 (4.7, 5.7)
	Second Infection, no intervening dose	6.2 (4.2, 8.8)
	Second infection, intervening dose	5.2 (4.5, 5.9)
Proliferation rate (Ct/day)	First infection, overall	3.6 (2.9, 4.4)
	First Infection, unvaccinated	3.3 (2.5, 4.1)
	First infection, vaccinated	3.7 (2.3, 5.7)
	Second infection, overall	2.8 (2.3, 3.4)
	Second Infection, no intervening dose	3.0 (1.7, 5.3)
	Second infection, intervening dose	2.7 (2.1, 3.5)
Clearance rate (Ct/day)	First infection, overall	1.6 (1.3, 1.8)
	First Infection, unvaccinated	1.5 (1.3, 1.8)
	First infection, vaccinated	1.6 (1.2, 2.2)
	Second infection, overall	2.4 (2.1, 2.7)
	Second Infection, no intervening dose	1.9 (1.1, 3.0)
	Second infection, intervening dose	2.3 (2.0, 2.8)

418

Supplementary Table 4. Viral kinetic parameters by variant.

Viral kinetic parameter	Category	Value
Peak viral concentration (Ct)	Other/None	26.7 (25.2, 28.0)
	Alpha	27.2 (24.7, 29.5)
	Delta	24.4 (21.8, 26.7)
	BA.1/BA.2	27.5 (26.6, 28.4)
Peak viral concentration (GE/ml)	Other/None	6.3 (6.0, 6.7)
	Alpha	6.2 (5.6, 6.9)
	Delta	7.0 (6.3, 7.7)
	BA.1/BA.2	6.1 (5.9, 6.4)
Proliferation time (days)	Other/None	4.0 (3.3, 4.9)
	Alpha	3.6 (2.6, 5.0)
	Delta	3.4 (2.3, 4.6)
	BA.1/BA.2	4.4 (3.7, 5.2)
Clearance time (days)	Other/None	9.1 (8.1, 10.3)
	Alpha	9.0 (7.2, 11.2)
	Delta	7.8 (6.3, 9.5)
	BA.1/BA.2	5.1 (4.6, 5.7)
Proliferation rate (Ct/day)	Other/None	3.3 (2.6, 4.1)
	Alpha	3.6 (2.4, 5.2)
	Delta	4.8 (3.2, 7.0)
	BA.1/BA.2	2.9 (2.3, 3.5)
Clearance rate (Ct/day)	Other/None	1.5 (1.2, 1.7)
	Alpha	1.4 (1.1, 1.9)
	Delta	2.0 (1.6, 2.6)
	BA.1/BA.2	2.4 (2.1, 2.8)

421 **Supplementary Table 5. Viral kinetic parameters for second infections in individuals with multiple**
 422 **infections, stratified by the variant of the first infection.**

423

Viral kinetic parameter	Category	Value
Peak viral concentration (Ct)	Other/None	27.3 (26.3, 28.2)
	Alpha	27.2 (25.1, 29.3)
	Delta	27.5 (25.3, 29.2)
Peak viral concentration (GE/ml)	Other/None	6.2 (5.9, 6.5)
	Alpha	6.2 (5.6, 6.8)
	Delta	6.1 (5.6, 6.7)
Proliferation time (days)	Other/None	4.4 (3.7, 5.2)
	Alpha	4.6 (3.3, 6.3)
	Delta	4.8 (3.5, 6.6)
Clearance time (days)	Other/None	5.0 (4.4, 5.6)
	Alpha	5.2 (4.1, 6.6)
	Delta	4.9 (3.8, 6.2)
Proliferation rate (Ct/day)	Other/None	2.9 (2.4, 3.5)
	Alpha	2.9 (1.9, 4.1)
	Delta	2.7 (1.8, 3.8)
Clearance rate (Ct/day)	Other/None	2.6 (2.2, 2.9)
	Alpha	2.5 (1.8, 3.3)
	Delta	2.6 (1.9, 3.5)

424

425

426
 427 **Supplementary Table 6. Correlation between viral kinetic parameters in first vs. second infections**
 428 **in individuals with two well-documented infections.** Significance was calculated using a permutation
 429 test, with the p -value representing the proportion of draws that exceeded the calculated significance value
 430 under the assumption of no association in viral kinetic parameters between the first and second infection.
 431 Bold values indicate significance at the $p = 0.05$ level.

432

Viral kinetic parameter	Correlation statistic	Value	Significance (p)
Peak viral concentration (Ct)	Spearman	0.0799	0.278
	Pearson	0.128	0.172
Proliferation time (days)	Spearman	0.267	0.0206
	Pearson	0.242	0.0396
Clearance time (days)	Spearman	0.475	0.0001
	Pearson	0.336	0.0081

433

434 **Supplementary Table 7. Correlation between viral kinetic parameters in first vs. second infections**
 435 **in individuals with two well-documented infections, stratified by the lineage of the first infection.**
 436 Significance was calculated using a permutation test, with the *p*-value representing the proportion of draws
 437 that exceeded the calculated significance value under the assumption of no association in viral kinetic pa-
 438 rameters between the first and second infection. Bold values indicate significance at the *p* = 0.05 level.

439


Viral kinetic parameter	Correlation statistic	First infection lineage	Value	Significance (<i>p</i>)
Peak viral concentration (Ct)	Spearman	Alpha	-0.308	0.828
		Delta	0.330	0.132
		Other/Unspecified	0.0675	0.346
	Pearson	Alpha	-0.299	0.828
		Delta	0.416	0.0717
		Other/Unspecified	0.0627	0.357
Proliferation time (days)	Spearman	Alpha	0.245	0.218
		Delta	0.418	0.074
		Other/Unspecified	0.180	0.156
	Pearson	Alpha	0.309	0.166
		Delta	0.462	0.0857
		Other/Unspecified	0.310	0.0241
Clearance time (days)	Spearman	Alpha	0.783	0.0019
		Delta	0.352	0.114
		Other/Unspecified	0.396	0.0121
	Pearson	Alpha	0.684	0.0054
		Delta	0.486	0.0525
		Other/Unspecified	0.233	0.108

440


441

442 **Supplementary Figure 1. Relative viral kinetic parameters for first vs. second SARS-CoV-2 infec-**
 443 **tions.** (A-C): Scatter plots of the raw individual-level mean posterior viral kinetic parameter values (points)
 444 for the peak viral concentration (A), proliferation time (B), and clearance time (C) for first vs. second infec-
 445 tions in individuals with two well-documented infections. Points are colored according to the variant of the
 446 first infection (Other/None: black; Alpha: blue; Delta: red); all second infections were caused by BA.1/BA.2.
 447 Dashed lines depict the best-fit linear regression to the parameter values when stratified by the variant of the
 448 first infection. The solid black line depicts the overall best-fit linear regression to the mean posterior
 449 parameter values combined across all first-infection variants. The grey regions depict the 95% confidence
 450 regions for this overall trend line.

451



452



453

454 **Acknowledgements.** The authors acknowledge Radhika Samant and Sarah Connolly for assis-
455 tance with data curation.

456

457

458 **Funding.** Supported in part by CDC contract #200-2016-91779, a sponsored research agree-
459 ment to Yale University from the National Basketball Association contract #21-003529, and the
460 National Basketball Players Association. Disclaimer: The findings, conclusions, and views ex-
461 pressed are those of the author(s) and do not necessarily represent the official position of the
462 Centers for Disease Control and Prevention (CDC).

463

464

465 **Data and code availability.**

466 All data and code needed to reproduce the findings in this manuscript may be accessed in the
467 following repository: https://github.com/skissler/Ct_SequentialInfections

468 **References.**

469

- 470 1. Klaassen, F. *et al.* Changes in population immunity against infection and severe disease from SARS-
471 CoV-2 Omicron variants in the United States between December 2021 and November 2022. *Medrxiv*
472 2022.11.19.22282525 (2022) doi:10.1101/2022.11.19.22282525.
- 473 2. Kojima, N., Shrestha, N. K. & Klausner, J. D. A Systematic Review of the Protective Effect of Prior
474 SARS-CoV-2 Infection on Repeat Infection. *Eval Health Prof* 44, 327–332 (2021).
- 475 3. Abu-Raddad, L. J., Chemaitelly, H., Bertollini, R. & Epidemiology, N. S. G. for C.-19. Severity of SARS-
476 CoV-2 Reinfections as Compared with Primary Infections. *New Engl J Med* 385, 2487–2489 (2021).
- 477 4. Bowe, B., Xie, Y. & Al-Aly, Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection.
478 *Nat Med* 28, 2398–2405 (2022).
- 479 5. Hay, J. A. *et al.* Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and
480 infection rebound: A retrospective cohort study. *Elife* 11, e81849 (2022).
- 481 6. Tom, M. R. & Mina, M. J. To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value. *Clin*
482 *Infect Dis* 71, ciaa619- (2020).
- 483 7. Hay, J. A. *et al.* Estimating epidemiologic dynamics from cross-sectional viral load distributions. *Sci-*
484 *ence* 373, eabh0635 (2021).
- 485 8. Ke, R. *et al.* Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in
486 infectiousness. *Nat Microbiol* 7, 640–652 (2022).
- 487 9. Puhach, O., Meyer, B. & Eckerle, I. SARS-CoV-2 viral load and shedding kinetics. *Nat Rev Microbiol* 1–
488 15 (2022) doi:10.1038/s41579-022-00822-w.
- 489 10. Wyllie, A. L. *et al.* Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. *New*
490 *Engl J Med* 383, 1283–1286 (2020).
- 491 11. Kissler, S. M. *et al.* Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Per-
492 sons. *New Engl J Med* 385, 2489–2491 (2021).
- 493 12. Kissler, S. M., Fauver, J. R., Mack, C. & others. Viral dynamics of SARS-CoV-2 variants in vaccinated
494 and unvaccinated persons. *England Journal of ...* (2021).
- 495 13. Cevik, M. *et al.* SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shed-
496 ding, and infectiousness: a systematic review and meta-analysis. *Lancet Microbe* 2, e13–e22 (2021).
- 497 14. Kissler, S. M. *et al.* Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and
498 public health strategies. *PLoS Biol.* 19, e3001333 (2021).
- 499 15. Yamaguchi, T., Shinagawa, T., Kobata, H. & Nakagawa, H. Immunity against seasonal human coro-
500 navirus OC43 mitigates fatal deterioration of COVID-19. *Int J Infect Dis* 109, 261–268 (2021).
- 501 16. Aydilto, T. *et al.* Immunological imprinting of the antibody response in COVID-19 patients. *Nat Com-*
502 *mun* 12, 3781 (2021).

- 503 17. Singanayagam, A. *et al.* Community transmission and viral load kinetics of the SARS-CoV-2 delta
504 (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, co-
505 hort study. *Lancet Infect Dis* 22, 183–195 (2022).
- 506 18. Vogels, C. B. F. *et al.* Multiplex qPCR discriminates variants of concern to enhance global surveil-
507 lance of SARS-CoV-2. *Plos Biol* 19, e3001236 (2021).
- 508 19. BaseSpace Labs. *DRAGEN COVID lineage*. (2021).
- 509 20. Rambaut, A. *et al.* A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epi-
510 demiology. *Nat Microbiol* 5, 1403–1407 (2020).
- 511 21. Aksamentov, I., Roemer, C., Hodcroft, E. & Neher, R. Nextclade: clade assignment, mutation calling
512 and quality control for viral genomes. *J Open Source Softw* 6, 3773 (2021).
- 513